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Recognition of nucleic acids as a signature of infec-
tion by Toll-like receptors (TLRs) 7 and 9 exposes
the host to potential self-recognition and autoimmu-
nity. It has been proposed that intracellular compart-
mentalization is largely responsible for reliable self
versus nonself discrimination by these receptors.
We have previously shown that TLR9 and TLR7
require processing prior to activation, which may
further reinforce receptor compartmentalization and
tolerance to self, yet this possibility remains un-
tested. Here we report that residues within the
TLR9 transmembrane (TM) region conferred the
requirement for ectodomain proteolysis. TLR9 TM
mutants responded to extracellular DNA, and mice
expressing such receptors died from systemic
inflammation and anemia. This inflammatory disease
did not require lymphocytes and appeared to require
recognition of self-DNA by dendritic cells. To our
knowledge, these results provide the first demon-
stration that TLR-intrinsic mutations can lead to a
break in tolerance.
INTRODUCTION
Toll-like receptors (TLRs) are receptors of the innate immune
system that have evolved to recognize conserved features of
microbes. A subset of TLRs (TLR3, TLR7, TLR8, and TLR9) link
the recognition of nucleic acids to induction of innate and adap-
tive immune responses (Medzhitov, 2007; Takeda et al., 2003).
Although this strategy enables detection of viral nucleic acid
within the degradative environment of intracellular compart-
ments, the cost of this strategy is the potential recognition of
self DNA and RNA, which has been implicated in autoimmune
diseases such as systemic lupus erythematosus and psoriasis
(Lande et al., 2007; Marshak-Rothstein, 2006). Accordingly,
regulatory mechanisms must exist that prevent responses to
self-derived nucleic acids. One such mechanism appears to be
the intracellular localization of TLR9 and TLR7, which sequesters
these receptors from extracellular self nucleic acid released fromInecrotic cells or apoptotic cells that undergo secondary necrosis
(Barton and Kagan, 2009; Marshak-Rothstein, 2006). Ligand
recognition occurs in endocytic compartments, although the
mechanistic details of receptor trafficking and localization
remain somewhat enigmatic and, in some cases, controversial
(Brinkmann et al., 2007; Ewald et al., 2008; Kim et al., 2008;
Latz et al., 2004; Leifer et al., 2004, 2006).
Nevertheless,mechanisms that facilitate delivery of self nucleic
acid to these compartments, such as internalization via surface
receptors or association with cationic peptides, can trigger TLR
activation (Lande et al., 2007; Leadbetter et al., 2002; Marshak-
Rothstein, 2006). It is noteworthy that all examples of TLR-medi-
ated recognition of self nucleic acids, especially in vivo, involve
aberrant ligand delivery as opposed to receptor intrinsic muta-
tions. One exception comes from our previous work in which we
showed that a chimeric TLR9-TLR4 receptor (TLR9N4C), which
traffics to the cell surface, gains the ability to respond to extracel-
lular vertebrate DNA in vitro (Barton et al., 2006). However, the
TLR4-basedsignalingof this receptorpreventedus fromperform-
ing definitive experiments regarding the effect of altered TLR9
localization (Barton et al., 2006). Unlike TLR9 that signals only
through the common TLR adaptor MyD88, TLR4 utilizes both
MyD88 and TRIF, another TLR adaptor, so the in vitro gain of
function we observed with this chimera can not be unequivocally
attributed to altered localization.Moreover, this receptor doesnot
result in autoimmune diseasewhen expressed in vivo (Figure S1A
available online). This lack of disease may be due to the inability
of this receptor to signal in plasmacytoid dendritic cells (pDCs)
and B cells but could also imply that additional regulatory mech-
anisms exist that prevent responses to self.
We and others have recently described another regulatory
step that may limit TLR activation to endolysosomes; namely,
the ectodomain of TLR9 is cleaved prior to receptor activation
(Ewald et al., 2008; Park et al., 2008). We have recently demon-
strated that TLR7 and TLR3 are similarly regulated, suggesting
that ectodomain proteolysis may be a general mechanism to
restrict nucleic acid sensing by TLRs to intracellular compart-
ments (Ewald et al., 2011). Receptor processing consists of at
least two distinct proteolytic steps mediated by asparagine
endopeptidase and cathepsins (Ewald et al., 2008, 2011; Park
et al., 2008; Sepulveda et al., 2009), and treatment of cells with
inhibitors of these proteases prevents TLR9, TLR7, and TLR3
activation (Ewald et al., 2011). An attractive possibility is that
this requirement for proteolysis by lysosomal proteases preventsmmunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc. 721
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TLR9 Mutations Induce Fatal Inflammationmislocalized receptors (e.g., receptors that access the cell
surface en route to the endolysosome) from responding to self
nucleic acid because they remain unprocessed and thus
nonfunctional (Barton and Kagan, 2009; Ewald et al., 2008). In
this way, the requirement for proteolysis may obviate the need
for strict receptor compartmentalization; however, the impor-
tance of receptor processing for maintaining tolerance to self
nucleic acid remains unexplored.
In the work reported here, we describe TLR9 mutants that no
longer require ectodomain proteolysis for activation. Expression
of these dysregulated receptors in mice results in lethal autoin-
flammatory disease. We find that this disease is independent
of B and T cells yet requires dendritic cells. Thus, dysregulated
activation of TLR9 can lead to autoinflammatory disorders in
certain contexts. Overall, this work clearly demonstrates that
mutations in TLR9 can break tolerance to self-nucleic acid. In
addition, we provide, to our knowledge, the first evidence that
receptor proteolysis has evolved to regulate self versus nonself
discrimination by nucleic acid-sensing TLRs.
RESULTS
Mutations in the TLR9 Transmembrane Domain Enable
Signaling in the Absence of Ectodomain Proteolysis
A direct way to test the role of receptor processing in self versus
nonself discrimination would be to express TLR9 truncation
mutants already lacking the portion of the ectodomain that is
normally removed by cleavage. We constructed a number of
different ‘‘precleaved’’ receptors, including a truncated TLR9
mutant recently reported to complement TLR9 deficiency (Park
et al., 2008); however, when expressed in HEK293T cells or
Tlr9/ macrophages, these receptors responded very poorly
or not at all to CpG oligonucleotides (ODN) (Figure S1B). Analysis
of N-linked sugars indicated that truncated TLR9 mutants were
unable to exit the endoplasmic reticulum (ER), presumably
because of misfolding of the ectodomains (Figure S1C). Thus,
we concluded that expression of pretruncated receptors would
not allow us to test the physiological relevance of receptor
cleavage for maintaining tolerance.
As an alternative approach, we sought to construct mutant
TLR9 receptors that bypass the requirement for ectodomain pro-
cessing prior to activation. Ligand binding studies indicate that
proteolysis does not regulate the receptor’s ability to bind
ligands; instead, processing of the ectodomain may be required
to allow ligand-bound receptors to undergo a conformational
change that initiates MyD88 recruitment and signal transduction.
Indeed, the initiation of signal transduction by TLR9 homodimers
appears to require a membrane proximal shift in the cytosolic
domains. These data as well as the presence of atypical amino
acids for a membrane spanning region led us to focus on the
transmembrane (TM) domain of TLR9 as potentially involved in
mediating the requirement for ectodomain processing. Our
strategy was to create a chimeric receptor (hereafter called
TLR9TM-MUT) in which the TLR9 TM region was replaced with
a more conventional, largely hydrophobic membrane spanning
sequence (Figure 1A).
To determine the impact of TM substitutions on TLR9
signaling, we tested the ability of cells expressing TLR9TM-MUT
to respond to TLR9 ligands. HEK293 cells transduced with722 Immunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc.TLR9TM-MUT responded to CpG ODN (with the nuclease-resis-
tant phosphorothioate backbone), although the response was
weak relative to cells expressing wild-type TLR9 (Figure 1B).
Similar results were observed in TLR9-deficient macrophages
and dendritic cells reconstituted with each receptor (Figure 1C;
Figure S1D). Remarkably, despite the reduced signaling of
TLR9TM-MUT to CpG DNA ligands mentioned above, activation
of TLR9TM-MUT was no longer blocked by bafilomycinA1 or
Z-FA-FMK (Figures 1D and 1E), compounds that potently block
receptor processing (Ewald et al., 2008, 2011; Park et al., 2008).
BafilomycinA1, in particular, leads to accumulation of a post-ER
full-length form of TLR9, the immediate precursor of the cleaved
receptor (Ewald et al., 2008). This unprocessed form of
TLR9TM-MUT also accumulated with Z-FA-FMK treatment (Fig-
ure 1F, see asterisk). However, in contrast to TLR9, this accumu-
lation of the full-length form of TLR9TM-MUT correlated with in-
creased responsiveness to ligands, further supporting the
conclusion that mutations in the TM enable TLR9TM-MUT to signal
independently of processing.
To test directly whether TLR9TM-MUT no longer requires
proteolytic processing prior to activation, we compared the abil-
ities of full-length wild-type TLR9 and full-length TLR9TM-MUT to
recruit MyD88 in response to ligand. As expected, in immortal-
ized TLR9-deficient macrophages reconstituted with N-terminal
FLAG-tagged TLR9, MyD88 did not associate with the full-length
receptor (isolated by FLAG immunoprecipitation) after stimula-
tion with CpG ODN (Figure 1G). These data agree with our
previous published findings that only cleaved TLR9 recruits
MyD88 (Ewald et al., 2008). In contrast, full-length TLR9TM-MUT
did recruit MyD88 under similar conditions (Figure 1G). This
difference was not due to defective signaling of the wild-type
TLR9-expressing cells, because both receptors were capable
of inducing tumor necrosis factor (TNF) production (Figure S1E).
Thus, mutations in the TM of TLR9TM-MUT enable signaling in the
absence of ectodomain processing.
TLR9TM-MUT Can Access the Cell Surface and Respond
to Extracellular Ligands
We next determined how bypassing the requirement for ectodo-
main processing impacts self versus nonself discrimination by
TLR9. We compared the responses of TLR9 and TLR9TM-MUT
to phosphodiester CpG ODN and salmon sperm genomic
DNA, ligands to which wild-type TLR9 responds poorly because
of degradation of ligands before reaching the TLR9-containing
endolysosome. TLR9TM-MUT responded robustly to both ligands
whereas TLR9 did not, suggesting that TLR9TM-MUT had gained
the ability to respond to ligands at the cell surface (Figure 2A).
To test this possibility directly, we compared the abilities of cells
expressing TLR9 and TLR9TM-MUT to respond to biotin-CpG
ODN immobilized by conjugation to streptavidin-coated plates.
Whereas cells expressing wild-type TLR9 were not activated,
TLR9TM-MUT-expressing cells responded robustly (Figure 2B).
These data indicate that bypassing the cleavage requirement
enables TLR9TM-MUT to access and respond to ligands at the
cell surface.
Whether TLR9 trafficking includes a plasma membrane step
is not well understood. Most studies have not detected the
receptor at the cell surface, although it remains possible that
the receptor localizes to the plasma membrane in certain cell
Figure 1. TLR9TM-MUT Does Not Require Processing for Activation
(A) Schematic of TLR9 and TLR9TM-MUT. TLR9TM-MUT consists of the ectodomain and cytosolic domain of TLR9 (blue) and the transmembrane domain of
TLR3 (yellow).
(B) TLR9TM-MUT can respond toCpGDNA ligands. HEK293 cells stably expressing aNF-kB luciferase reporter and TLR9 or TLR9TM-MUT were stimulatedwith CpG
ODN (phosphorothioate backbone) as indicated and luciferase activity was measured 16 hr later.
(C) Macrophages expressing TLR9TM-MUT respond to CpG ODN and extracellular genomic DNA. TLR9-deficient macrophages transduced with retroviruses
encoding TLR9, TLR9TM-MUT, or empty vector (control) were stimulated as indicated and the percentage of GFP-positive cells producing TNF was measured by
intracellular staining and flow cytometry. Data shown are representative of two experiments.
(D and E) Signaling by TLR9TM-MUT does not require proteolysis. TLR9-deficient macrophages expressing TLR9 or TLR9TM-MUT were pretreated with bafilo-
mycinA1 for 2 hr (D) or Z-FA-FMK overnight (E), stimulated with CpG ODN, and stained to measure TNF production, as described in (C).
(F) Stabilization of shifted form of TLR9TM-MUT in the presence of Z-FA-FMK. Anti-HA immunoblot of TLR9 and TLR9TM-MUT from lysates of macrophage treated
with DMSO (vehicle) or Z-FA-FMK. Open triangle indicates full-length TLR9. Asterisk denotes the shifted form of the full-length receptor. Immunoblot shown is
representative of two experiments.
(G) Full-length TLR9TM-MUT can recruit MyD88. TLR9-deficient macrophages expressing N-terminal FLAG-TLR9 or FLAG-TLR9TM-MUT were stimulated with CpG
ODN and recruitment of MyD88 was measured by immunoprecipitation (IP) and immunoblot (IB) as indicated. The immunoblot of whole cell lysates (WCL) shows
equivalent amounts of MyD88. Data shown are representative of two experiments. Unless stated otherwise, experiments in this figure were performed at least
three times with similar results.
Error bars indicate standard deviation of averages shown. See also Figure S1.
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TLR9 Mutations Induce Fatal Inflammationtypes or transiently during an intermediate trafficking step (Latz
et al., 2004; Lee et al., 2006). To examine these possibilities for
TLR9 and TLR9TM-MUT, we measured surface expression of
N-terminal FLAG-tagged receptors by flow cytometry. Use of
an N-terminal tag allows us to assess how much, if any, of the
unprocessed receptors are at the cell surface. TLR9TM-MUTIwas clearly detectable on the cell surface at amounts higher
than TLR9 albeit less than TLR2 (Figure 2C). This difference in
localization was not due to differences in overall expression, as
shown by the fact that anti-FLAG immunoblot revealed similar
amounts of each protein, and the expression of a bicistronic
human CD2 reporter was similar (Figure 2C, inset; Figure S2A).mmunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc. 723
Figure 2. TLR9TM-MUT Can Access the Cell Surface and Responds to Extracellular Ligands
(A) TLR9TM-MUT is more responsive to extracellular DNA ligands. Luciferase assays were performed as described in (B) except stimulations were with either
phosphodiester (PD) backbone CpG ODN or salmon sperm DNA (V. DNA). Data shown are representative of two experiments.
(B) TLR9TM-MUT can respond to immobilized CpG ODN at the cell surface. Cells described in Figure 1B were plated on streptavidin-coated plates to which
biotinylated-CpG ODN had been previously conjugated. Luciferase activity was measured in lysates after 6 hr.
(C) Full-length TLR9TM-MUT is expressed at the cell surface. Flow cytometry histograms of anti-FLAG staining of HEK293T cells stably expressing N-terminal
FLAG-TLR9 (gray), FLAG-TLR9TM-MUT (black), FLAG-TLR2 (blue), or empty vector control (shaded). Anti-FLAG immunoblot of whole cell lysates (WCL) of the
indicated cells (inset). See also Figure S2A.
(D) The ectodomain of TLR9TM-MUT is processed inefficiently. Anti-HA immunoblot of lysates from TLR9-deficient macrophages expressing C-terminally
HA-tagged TLR9 or TLR9TM-MUT. Open triangle indicates full-length TLR9. Closed triangle indicates processed TLR9. Asterisk denotes the shifted form of the
full-length receptor.
(E) TLR9TM-MUT traffics through the Golgi apparatus. Immunoprecipitated TLR9 or TLR9TM-MUT frommacrophage lysates were treatedwith Endoglycosidase H (E)
or PNGase F (P) or left untreated (U).
(F) TLR9 and TLR9TM-MUT exit the ER with similar efficiency and kinetics. Pulse-chase analysis of macrophages expressing TLR9 or TLR9TM-MUT. TLR9
or TLR9TM-MUT were harvested at the indicated chase times, immunoprecipitated, and visualized by SDS-PAGE.
Data presented are representative of at least three independent experiments. Error bars indicate standard deviation of averages shown.
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of TLR9TM-MUT, the cleaved form of TLR9TM-MUT was reduced
relative to wild-type TLR9, suggesting that TLR9TM-MUT does
not efficiently traffic to the endolysosome (Figure 2D, filled
arrowheads). This reduction in processing was not due to ineffi-
cient ER exit, because the shifted form of the full-length receptor
(representing the pool of TLR9 that has exited the ER and
trafficked through the Golgi) was detectable in cells expressing
TLR9TM-MUT (see asterisk in Figure 2D). As expected, this shifted
form of the protein was resistant to endoglycosidase H (endoH)
treatment (Figure 2E; Ewald et al., 2008). Pulse-chase analysis724 Immunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc.confirmed that the post-ER full-length forms of TLR9 and
TLR9TM-MUT appeared with similar kinetics (asterisk in Figure 2F).
However, the shifted form of TLR9TM-MUT was more stable than
the shifted form of TLR9 (Figure 2F, 3 hr versus 4 hr), which
agrees with the slightly higher amounts of TLR9TM-MUT at the
cell surface. Finally, as expected, TLR9TM-MUT signaling still
required the ER-resident protein, Unc93b1 (Figure S2B), and
expression of TLR9TM-MUT did not perturb the balance between
Unc93b1 and other nucleic acid-sensing TLRs, because TLR7
and TLR3 responses were largely unaltered in TLR9TM-MUT-ex-
pressing DCs and macrophages (Figures S1D and S2C).
Figure 3. Expression of TLR9TM-MUT In Vivo Leads to Fatal Inflammation
(A) Schematic of the approach used to express TLR9 or TLR9TM-MUT in mice. Hematopoietic stem cells (HSCs) from TLR9-deficient mice were transduced with
retroviruses encoding TLR9, TLR9TM-MUT, or vector control followed by transfer into lethally irradiated C57BL/6 recipient mice.
(B) Mice expressing TLR9TM-MUT die from inflammatory disease. Survival plot of radiation chimeric mice receiving HSCs expressing either TLR9, TLR9TM-MUT, or
empty vector (control).
(C) TLR9TM-MUT-expressing mice develop anemia. Mean values of hematocrit, red blood cells (RBCs), and hemoglobin (Hg) in the blood of mice at day 19 post-
HSC transfer.
(D) Expression of TLR9TM-MUT in mice causes an expansion of DCs. Graph showing the total number of GFP-positive, CD11c+ cells in the bone marrow at day 19
after injection of HSCs.
(E) TLR9TM-MUT expression leads to inflammatory cytokine induction. TNF was measured in sera from the indicated mice at day 19–29 post-HSC transfer. Each
point represents an individual mouse. Horizontal line represents the mean.
(F) Expression of TLR9TM-MUT in mice leads to block in B cell development. The total number of CD19+ cells in the bonemarrow and spleens of the indicatedmice,
as measured by flow cytometry, is shown.
Error bars indicate standard deviation of averages shown. Unless stated otherwise, experiments in this figure were performed at least three times with similar
results. See also Figure S3.
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Autoinflammatory Disease
Because the TM mutations enable TLR9TM-MUT to signal inde-
pendently of ectodomain proteolysis, we used TLR9TM-MUT to
test the relevance of this regulatorymechanism in vivo.We trans-
duced TLR9-deficient hematopoietic stem cells (HSCs) with
retroviruses encoding TLR9, TLR9TM-MUT, or empty vector
(control) and transferred these HSCs into lethally irradiated
C57BL/6 recipients (Figure 3A). HSCs were transduced with
similar efficiencies and expressed similar amounts of GFP driven
from a bicistronic vector (Figure S3A). Strikingly, all mice
receiving TLR9TM-MUT HSCs died within 4 weeks of transfer
whereas mice receiving control or TLR9 HSCs remained healthy
and viable (Figure 3B).
TLR9TM-MUT-expressing mice were profoundly anemic, as
measured by hematocrit, erythrocyte, and hemoglobin countsI(Figure 3C). The overall cellularity of bone marrow in
TLR9TM-MUT-expressing mice was reduced relative to TLR9-
expressingmice, whereas the cellularity of the spleenwas similar
between all groups (Figures S3C and S3D). Analysis of the
cellular composition of bone marrow and spleens from
TLR9TM-MUT-expressing mice revealed an expansion of
CD11c+ cells relative to mice receiving TLR9 and control trans-
duced HSCs (Figure 3D; Figures S3B and S3E). Moreover,
TLR9TM-MUT-expressingmice had elevated amounts of a number
of inflammatory cytokines, including TNF, Rantes, and inter-
leukin-18 (IL-18), consistent with TLR9TM-MUT activation in DCs
(Figure 3E; Figure S3H). Surprisingly, the bone marrow and
spleens of TLR9TM-MUT mice had drastically reduced numbers
of CD19+ B cells, indicating a block in B cell development at
an early stage (Figure 3F). B cell development was blocked for
both transduced and nontransduced cells, supporting themmunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc. 725
Figure 4. TLR9TM-MUT-Mediated Inflammatory Disease Is Driven by CD11c+ Dendritic Cells
(A and B) Disease caused by TLR9TM-MUT does not require B or T cells. Experiments were performed as in Figures 3B–3D, except Rag1-deficient HSCswere used
to generate chimeric mice.
(A) Survival plot of chimeric mice receiving transduced HSCs of the indicated genotypes.
(B) Blood analyses at day 19 post-HSC transfer are shown. The data shown are representative of two independent experiments.
(C) Surface phenotype of CD11c+ cells in TLR9TM-MUT radiation chimeras. Bone marrow cells from radiation chimeras expressing the indicated receptors were
analyzed for cell surfacemarker expression by flow cytometry (day 20 posttransfer). The histograms show expression of the CD11b, MHC class II, and SiglecH on
GFP-gated CD11c+ cells. Representative histograms are shown for individual mice in two separate experiments containing four mice.
(D and E) CD11c+ cells are required for inflammatory disease in TLR9TM-MUT mice.
(D) Schematic of experimental setup for depletion of CD11c+ cells in radiation chimeras expressing TLR9TM-MUT. Mice were given either PBS or diphtheria toxin
(DT) every 5 days after introduction of TLR9TM-MUT-transduced HSCs and analyzed 20 days after HSC injection.
(E) Block in B cell development and anemia seen in TLR9TM-MUT radiation chimeras is rescued by depletion of CD11c+ cells. The total number of CD19+ cells in the
spleens of the indicated mice as well as mean hematocrit are shown for PBS or diphtheria toxin (DT)-treated mice.
Error bars indicate standard deviation of averages shown. Data are representative of two experiments with four mice per group. See also Figures S4A and S4B.
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defects in HSCs (Figure S3G). No abnormalities in the blood by
complete blood count (CBC) or in the cellular composition of
the spleen and bone marrow were observed in mice receiving
control or TLR9-expressing HSCs (Figures 3C–3F).
TLR9TM-MUT-Induced Autoinflammatory Disease Is
Independent of B and T Cells but Dependent on CD11c+
Dendritic Cells
The expansion of DCs and lack of B cells suggested that disease
in TLR9TM-MUT mice was driven by DC activation and did not726 Immunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc.require autoantibody production. To test this possibility directly,
we generated radiation chimeras by using retrovirally trans-
duced HSCs from Rag1-deficient mice. Mice receiving wild-
type or Rag1-deficient HSCs expressing TLR9TM-MUT developed
similarly severe disease, indicating that lymphocytes were not
required for TLR9TM-MUT-induced disease (Figures 4A and 4B).
Therefore, we considered the possibility that expression of
TLR9TM-MUT on DCs enabled these cells to recognize DNA
released from apoptotic cells undergoing secondary necrosis,
as might be expected in irradiated mice. Consistent with this
hypothesis, we detected increased DNA in the sera of irradiated
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TLR9 Mutations Induce Fatal Inflammationmice (Figure S4C). Moreover, expansion of DCs was observed
only in GFP-positive cells, indicating that this aspect of the
phenotype was cell autonomous and required TLR9TM-MUT
(Figures S3E and S3F). These DCs expressed high amounts of
MHC class II, CD11b, and CD11c but were negative for sialic
acid Ig-binding lectin-H (SiglecH), which suggests that they
were conventional DCs (Figure 4C).
To test more directly the role of DCs in TLR9TM-MUT-mediated
disease, we transduced HSCs from mice expressing the diph-
theria toxin receptor driven by the CD11c promoter (CD11c-
DTRmice) and transferred these HSCs into irradiated recipients.
Injecting these radiation chimeras with diphtheria toxin (DT)
depleted CD11c-positive cells and prevented anemia and B
cell depletion, whereas mice receiving saline still developed
disease typical of TLR9TM-MUT-expressing mice (Figures 4D
and 4E; Figure S4A). As expected, the rescue mediated by DT
was apparent only when HSCs expressing CD11c-DTR were
used, ruling out any nonspecific effects of DT treatment
(Figure S4B). Collectively, these data indicate that DCs in
TLR9TM-MUT-expressing mice are necessary for the anemia
and B cell depletion, though we cannot formally rule out that
another CD11c-positive population of cells is depleted by DT
treatment and contributes to disease. Importantly, these results
further support that the observed inflammatory disease is not
simply due to cell-autonomous defects in the HSCs associated
with ectopic TLR9TM-MUT expression because depletion of
a specific cell type rescues these mice from disease.Autoinflammatory Disease in TLR9TM-MUT Mice Is
Partially Rescued in the Absence of TNF but Remains
Intact in Interferon-a Receptor-Deficient Mice
Systemic inflammation may account for the anemia and B cell
deficiency observed in TLR9TM-MUT mice, because inflammatory
mediators such as TNF and type I interferon (IFN) have been
shown to negatively impact B cell development and erythropoi-
esis (Lin et al., 1998; Ueda et al., 2004, 2005; Yamada et al.,
1991; Zoumbos et al., 1985). Indeed, when we generated radia-
tion chimeras using Tnfa/Lta/Ltb/ HSCs, the mice ex-
pressing TLR9TM-MUT showed prolonged survival, reduced
anemia, and less severe B cell depletion (Figures 5A–5C and
data not shown). Using mice lacking the type I IFN receptor
(IFNAR) or IFNAR-deficient HSCs, however, did not ameliorate
the disease (Figures 5D–5F; Figures S5A–S5D), which was
consistent with our observation that the expanded DCs did not
express the plasmacytoid DC marker SiglecH (Figure 4C), and
we could not detect elevated amounts of type I interferon in
the serum of these mice (data not shown).
Although these data suggested that bypassing the require-
ment for ectodomain proteolysis leads to a break in tolerance,
an alternative interpretation is that TLR9TM-MUT has altered
signaling properties or engages pathways not normally acces-
sible to wild-type TLR9. We tested this possibility by determining
the role of known TLR9 signaling components in TLR9TM-MUT-
based disease. As expected for a receptor with unaltered down-
stream signaling, the disease was entirely MyD88 dependent
and did not require TRIF (Figures S5E–S5G). These data, along
with our in vitro studies (Figures S1D and S1E), argue that the
TLR9TM-MUT signaling pathways are unaltered relative to wild-Itype TLR9, other than the ability to access extracellular ligands
at the cell surface and signal independently of cleavage.
Altering Five Amino Acids within the TLR9
Transmembrane Region Is Sufficient to Cause
Autoinflammatory Disease
The striking phenotype associated with expression of the
TLR9TM-MUT receptor suggests that elements of the TLR9 TM
impose the requirement for ectodomain proteolysis. Loss of
this regulation can result in systemic inflammatory disease. To
define more precisely which residues are required to maintain
TLR9 tolerance, we made additional mutants (TLR9TM-MUT2,
TLR9TM-MUT3, and TLR9TM-MUT4) in which fewer residues within
the TLR9 TM domain were altered (Figure 6A). Analysis of the
processing of each receptor indicated that only one of the
mutants, TLR9TM-MUT4, recapitulated the altered trafficking and
proteolysis we had observed with TLR9TM-MUT (Figure 6B).
Moreover, TLR9TM-MUT4 responded, albeit more weakly than
TLR9TM-MUT, to plate-bound CpG ODN and was insensitive to
protease inhibitors, whereas TLR9TM-MUT2 and TLR9TM-MUT3
behaved like wild-type TLR9 in these assays (Figures 6C and
6D). Consistent with these functional data, the amounts of
TLR9TM-MUT4 on the cell surface were below our detection
limit (data not shown). Altogether, these data suggest that
TLR9TM-MUT4 has a weaker gain-of-function phenotype than
TLR9TM-MUT. Nevertheless, mice receiving HSCs expressing
TLR9TM-MUT4 succumbed to inflammatory disease characterized
by severe anemia much like TLR9TM-MUT-expressing mice,
whereas TLR9TM-MUT2- and TLR9TM-MUT3-expressing mice
were unaffected (Figure 6E). These results indicate that replace-
ment of only five amino acids (Leu, Ser, Trp, Asp, and Cys) within
the TLR9 TM is sufficient to render the receptor self reactive,
although we cannot formally rule out that these residues are
positioned just outside the TM region rather than within the
membrane. Regardless, this region of the protein clearly plays
a key regulatory role in vivo.
DISCUSSION
The results presented here demonstrate that mutations within
a TLR can result in a break of tolerance. There are many exam-
ples of autoimmune or autoinflammatory diseases resulting
from perturbations in cell-extrinsic pathways that ultimately
lead to excessive generation or altered delivery of self-ligands
for innate immune receptors (Hanayama et al., 2004; Mevorach
et al., 1998; Napirei et al., 2000; Yasutomo et al., 2001; Yoshida
et al., 2005). One key piece of evidence indicating that TLR9 can
contribute to the break in tolerance in autoimmune disease has
been work demonstrating TLR9’s ability to synergize with autor-
eactive B cell antigen receptors bound to antibody-chromatin
immune complexes and lead to potent activation of these cells
(Leadbetter et al., 2002). This work has suggested that TLR9
signaling in response to self-DNA can lead to the production of
potentially pathological self-reactive antibodies, probably due
to delivery of ligands to intracellular compartments. What distin-
guishes our work from these previous studies is the finding that
receptor-intrinsic mutations can alter TLR activation and break
tolerance to self. The biophysical changes associated with signal
transduction remain poorly described for TLR family members,mmunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc. 727
Figure 5. Lack of TNF and Lymphotoxin ab but Not IFNAR Partially Rescues Inflammatory Disease in TLR9TM-MUT-Expressing Mice
(A–C) Autoinflammatory disease mediated by TLR9TM-MUT is partially ameliorated in the absence of TNF and lymphotoxinab.
(A) Schematic of bone marrow chimera experiment to address role of TNF in TLR9TM-MUT-mediated disease.
(B) Partial recovery of B cell development in TLR9TM-MUT-expressing radiation chimeras generated with Tnfa/Lta/Ltb/HSCs. The number of CD19+ B cells
in the bone marrow (BM) and spleen (SPL) of TLR9 and TLR9TM-MUT-expressing radiation chimeras in C57BL/6 or Tnfa/Lta/Ltb/ cells (day 20 posttransfer)
is shown.
(C) Tnfa/Lta/Ltb/ TLR9TM-MUT-expressing mice do not develop anemia at early time points. Mean values of hematocrit in the blood of mice at day 20 post-
HSC transfer. Data shown are representative of two experiments.
(D–F) Loss of Ifnar1 does not rescue TLR9TM-MUT-mediated disease in vivo.
(D) Schematic of bonemarrow chimera experiment to address role of type I interferon in TLR9TM-MUT-mediated disease. Initial experiment utilized IFNAR-deficient
or C57BL/6 donors.
(E) Expression of TLR9TM-MUT with IFNAR-deficient HSCs in mice causes an expansion of dendritic cells similar to wild-type. Graph showing the average number
of GFP-gated CD11c+ cells in the bone marrow and spleen at day 25 after injection of HSCs.
(F) TLR9TM-MUT expression in IFNAR-deficient HSCs expressingmice develop severe anemia.Mean values of hematocrit, red blood cells (RBCs), and hemoglobin
(Hg) in the blood at day 25 post-HSC transfer.
Error bars indicate standard deviation of averages shown. See also Figure S5.
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regulatory role for TLR9 and impose the requirement for ectodo-
main processing that is necessary to avoid self recognition.
Use of radiation chimeras in our studies demonstrated that
bypassing the requirement for TLR9 ectodomain processing
enabled cells to respond to self-DNA released from dying cells.
Activation of these cells resulted in production of inflammatory
cytokines that fed back on hematopoiesis. The features of
inflammatory disease that we describe here are similar to those
observed in other models of dysregulated innate immune activa-
tion (Deane et al., 2007; O’Connell et al., 2008; Yoshida et al.,728 Immunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc.2005). Most relevant to our work is the recent observation that
repeated CpG ODN injection in mice leads to inflammatory
disease that is independent of B and T cells and results in anemia
(Behrens et al., 2011). Additionally, transgenic mice overex-
pressing TLR7 develop a lupus-like disease characterized by
DC activation and anemia within 2 to 10 months (Deane et al.,
2007). Importantly, though, the disease in TLR9TM-MUT-express-
ing animals is much more acute and cannot simply be attributed
to overexpression, because TLR9-expressing mice in our
system are healthy in the time frame analyzed. Anemia is also
observed in DNase II-deficient mice, which produce type I IFN
Figure 6. TLR9 TM Mutants Identify Residues Critical in Preventing Self-Reactivity
(A) Schematic showing an alignment of TM regions of TLR9mutants. Underline indicates residues from TLR9. Arrowhead indicates the last conserved cysteine of
the ectodomain.
(B) TLR9TM-MUT4 has altered trafficking to the endolysosome. Anti-HA immunoblots of lysates from TLR9-deficient macrophages expressing the indicated TLR9
TM mutants, as described in (A).
(C) TLR9TM-MUT4 can respond to ligands at the cell surface. HEK293 cells stably expressing TLR9 or the indicated TLR9 mutants were plated on streptavidin-
coated plates to which biotinylated CpG ODN had been previously conjugated. Luciferase activity was measured in lysates after 6 hr.
(D) TLR9TM-MUT4 activation does not require proteolysis. TLR9-deficientmacrophages expressing the indicated TLR9 TMmutants were stimulatedwith CpGODN
after treatment with DMSO (vehicle) or Z-FA-FMK. TNF production was measured by flow cytometry. The data are normalized for each TLR9 TM mutant by
dividing by the percentage of responding cells in vehicle-treated control samples.
Results shown for (B)–(D) are representative of at least three experiments.
(E) TLR9TM-MUT4 induces inflammatory disease in vivo. Mean values of hematocrit, red blood cells (RBCs), and hemoglobin (Hg) in the blood of mice at day 19
post-HSC transfer.
Error bars indicate standard deviation of averages shown. Data are representative of two independent experiments.
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(Yoshida et al., 2005). The disease induced by TLR9TM-MUT
was not rescued in IFNAR-deficient mice but was partially
ameliorated when HSCs lacking the genes encoding TNF, lym-
photoxin a, and lymphotoxin b were used, suggesting that a
combination of inflammatory cytokines may be responsible for
the hematopoietic defects in these mice. The resulting anemia
we observed in TLR9TM-MUT-expressing mice was accompanied
by reduced white blood cells, red blood cells, and platelet
counts, which is similar to aplastic anemia in humans, a form
of anemia that is largely idiopathic and correlates with increases
in serum TNF.
One unexpected aspect of the disease was the independence
of disease progression on B and T cells. However, as mentioned
earlier, recent in vivo studies with repeated CpG ODN injectionIleads to an inflammatory disease that did not require lympho-
cytes (Behrens et al., 2011). Disease progression is also RAG
independent in the autoinflammatory arthritis observed in
DNaseII-IFNAR double-deficient mice (Kawane et al., 2010). In
our model, this independence may be due to the severity of
the phenotype resulting from the abundance of self-nucleic
acid that is present after irradiation and the presence of a dysre-
gulated mutant of TLR9 that can respond to those ligands.
Although the observed disease is not lupus-like, it clearly affirms
the gain of function to self nucleic acid we initially observed
in vitro; the resulting loss of self-tolerance in vivo demonstrates
the importance of the necessity for linking receptor function
with proteolysis within intracellular compartments.
Perhaps the most surprising aspect of our study was that the
TM region of TLR9 conferred the regulatory requirement formmunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc. 729
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mediate this regulation remains unclear. Experiments using split
green fluorescent protein (GFP) molecules fused to the TLR9
ectodomain and TM indicate that receptor activation leads to
increased proximity of TM domains within the TLR9 dimer (Latz
et al., 2007). Previous work from our group has shown that
both cleaved and uncleaved TLR9 can bind CpG ODN, yet
adaptor recruitment and receptor activation is only a property
of cleaved receptors (Ewald et al., 2008). Thus, amino acids
within the TLR9 TM domain may prevent the formation of this
active conformation prior to processing of the ectodomain.
Therefore, we postulate that TLR9TM-MUT has gained the ability
to undergo ligand-induced conformational changes in the
absence of cleavage because of alteration of these residues in
the TM. Notably, the disrupted TM region did not result in consti-
tutive activation of TLR9TM-MUT because signaling did not occur
in the absence of ligand. Structural studies of TLR9 may provide
clarity on whether the ectodomain conformation after ligand
binding is indeed altered upon cleavage of receptor.
Although the requirement for processing is common to all
nucleic acid-sensing TLRs, it is becoming increasingly clear
that these TLRs are each regulated through distinct mecha-
nisms. For example, as mentioned previously, TLR7 overexpres-
sion is sufficient to break tolerance in vivo (Deane et al., 2007).
However, the lack of disease in wild-type TLR9-expressing
radiation chimeras suggests that the disease in mice expressing
TLR9TM-MUT is due to a different form of dysregulation and not
simply overexpression. Additionally, in the MRL/lpr model of
lupus, TLR9-deficient animals have exacerbated disease
whereas TLR7-deficient mice are partially protected (Christen-
sen et al., 2006). This surprising result suggests that, despite
similar expression profiles and signaling by both receptors, there
are important differences in the regulation of TLR7 and TLR9 that
influence responses to self-ligands that remain poorly under-
stood. Whether the proteolysis of TLR7 and TLR3 is regulated
through residues within the TM of these receptors is not yet
clear, and it is possible that there are other regions of these
proteins that regulate processing for each receptor. We attemp-
ted to make a comparable ‘‘TLR7TM-MUT,’’ but we were unable
to generate a functional receptor. There is little similarity
between the TM regions of these receptors, which may suggest
that regulation of proteolysis occurs through distinct mecha-
nisms for each of the nucleic acid-sensing TLRs.
It is also possible that the TLR9 TM mediates interaction with
an as-yet-unidentified regulatory protein that influences
signaling and trafficking of the receptor. It is notable that this
region of TLR9 contains an aspartic acid (D818), which is quite
unusual in TM domains. Charged residues within TM domains
can mediate association with other proteins, or in this case
may govern the interactions between the TM domains within
the TLR9 dimer (Latz et al., 2007). Our strategy did not directly
address the importance of D818; however, a TLR9 mutant with
only D818 changed to alanine was inhibited by protease inhibi-
tors similarly to wild-type TLR9, indicating that this amino acid
does not, by itself, dictate the requirement for ectodomain prote-
olysis (data not shown). Therefore, it seems likely that multiple
residues cooperate to confer this regulation or that the pheno-
types of TLR9TM-MUT and TLR9TM-MUT4 are dependent on the
precise amino acids that we substituted into these receptors.730 Immunity 35, 721–732, November 23, 2011 ª2011 Elsevier Inc.Regarding the likelihood that mutations in the TM region of
TLR9 could predispose individuals to autoimmune or autoinflam-
matorydisorders, theseverephenotypeobserved inTLR9TM-MUT-
expressing mice suggests that similar alleles in humans may be
fatal as congenital mutations. For this reason, genome-wide
association studies may be unlikely to identify such mutations,
unless certain substitutions result in less severe, nonfatal alleles.
In our system, we were unable to identify any substitutions that
resulted in such alleles, although this possibility certainly remains
possible. It would seem more likely, though, that TM mutations
could play a role in somatic cells, resulting in rare cells with self-
reactive TLRs. These cells may facilitate the initial break in toler-
ance responsible for certain autoimmune disorders.
EXPERIMENTAL PROCEDURES
Reagents
All chemicals and reagents, unless noted otherwise, were purchased from
Fisher Scientific. CpG ODN (TCCATGACGTTCCTGACGTT, all phosphoro-
thioate linkages) and 50-biotinylated CpG ODN of the same sequence were
from Integrated DNA Technologies. LPS, salmon sperm DNA (endotoxin
free), and R848 were purchased from Invivogen. poly(I:C) was purchased
from Sigma. GM-CSF was purchased from Peprotech. The following anti-
bodies were from eBioscience unless otherwise stated: anti-HA (clone 3F10,
Roche), anti-FLAG (M2 and M5, Sigma), polyclonal anti-MyD88 (Enzo),
PE-Cy7-conjugated anti-CD11c (N418), PE-Cy5-conjugated anti-B220
(RA3-6B2), PE-conjugated anti-TNF (MP6-XT22), PE-Cy7-conjugated CD19
(1D3), PE-Cy5-conjugated anti-CD2 (RPA-2.10, BDBiosciences), APC-Alexa
750-conjugated anti-CD11b (M1/70), APC-conjugated anti-MHC II (M5), Alexa
647-conjugated anti-SiglecH (ebio440c), and Alexa 647 goat anti-mouse IgG
(Invitrogen). TNF was quantified in cell culture supernatants with the CBA
mouse inflammation kit (BD Biosciences).
DNA Cloning
TLR9TM-MUT was constructed by ‘‘PCR sewing’’ of cDNA corresponding to
amino acids 1–810 and 834–1032 of mouse TLR9 and amino acids 698–720
of mouse TLR3. cDNA encoding precleaved TLR9 (corresponding to amino
acids 471–1032) was kindly provided by H. Ploegh (MIT). All TLR-encoding
cDNAs were cloned into the mouse stem cell virus-based retroviral
vector MSCV2.2, provided by M. Schlissel (UC Berkeley). TLR9-HA and
TLR9TM-MUT-HA were constructed by the addition of a hemagglutinin epitope
(YPYDVPDYA) to the C-terminal end of each receptor in MSCV2.2. Unc93b1
and the nonfunctional H412R mutant were cloned into MSCV2.2. Flag TLR9
and Flag TLR9TM-MUT were constructed in pCMV-Flag-8 (Sigma) and were
then transferred into MigR2 (a MSCV2.2-based vector in which GFP has
been replaced by human CD2).
Cell Lines, Plasmids, and Tissue Culture
HEK293 and HEK293T cells were from American Type Culture Collection.
Cell lines were cultured in DMEM supplemented with 10% (vol/vol) FCS,
L-glutamine, penicillin-streptomycin, sodium pyruvate, and HEPES (pH 7.2)
(Invitrogen). Macrophages and DCs were cultured in M-CSF and GM-CSF,
respectively, containing RPMI-1640 medium supplemented with 10% (vol/vol)
FCS, L-glutamine, penicillin-streptomycin, sodium pyruvate, and HEPES
(pH 7.2), as previously described (Barbalat et al., 2009). Unless otherwise
noted, stable lines were generated by transducing cells with MSCV2.2 retrovi-
ruses encoding the target cDNA. Immortalized macrophages were generated
as previously described (Blasi et al., 1985). In brief, bone marrow-derived
macrophages were cultured in supernatant containing M-CSF as well as virus
encoding both v-raf and v-myc. After 8 days, macrophages were removed
from M-CSF-containing media and cultured in RPMI-1640 media with added
supplements as described above.
Mice
C57BL/6, Rag1/, and Tnfa/Lta/Ltb/mice were purchased from Jack-
son Laboratories. Tlr9/, Ticam1/ (referred to as TRIF in the text), and
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seven generations onto the C57BL/6 background. Ifnar1/ mice on the
C57BL/6 background were provided by D. Portnoy (UC Berkeley). CD11c-
DTR transgenic mice (Jung et al., 2002) on the C57BL/6 background were
kindly provided by the Cancer Research Lab at UC Berkeley. Unc93b13d/3d
mice (generated by B. Beutler) were obtained from the MMRRC at UC Davis.
All mice were housed in the animal facilities at the University of California, Ber-
keley according to guidelines of the Institutional Animal Care and Use
Committee.
Retroviral Transduction
Transduction of HSCs was performed by first enriching for HSCs by isolating
bone marrow from donor mice that had been injected intraperitoneally 4 days
earlier with 5 mg of 5-fluorouracil. Cells were cultured in stem cell media
(DMEM supplemented with 15% FCS, 10 mM sodium pyruvate, 2 mM L-gluta-
mine, 100 U/ml penicillin, 100 g/ml streptomycin, 100 ng/ml stem cell factor,
10 ng/ml IL-6, 10 ng/ml IL-3, cytokines from R&D systems). 48 hr later, these
cells were transduced with retroviral supernatant (supplemented with stem
cell factor, IL-6, IL-3, and polybrene) on two successive days. Virus was
produced with the ØNX-E packaging line (provided by G. Nolan, Stanford
University). After the second transduction, cells were washed three times
with PBS before injection into recipient mice. For retroviral transduction of
immortalized macrophages, VSV-G-psuedotyped retroviral supernatant was
made with GP2-293 packaging cells as previously described (Ewald et al.,
2008).
Bone Marrow Chimera Mice
At least 1 week before irradiation and BM transfer, mice were placed on
trimethoprim-sulfamethoxazole (via drinking water). Recipient mice received
lethal total body irradiation (1000 rad) from a 137Cs source. 24 hr later, they
were reconstituted with syngeneic HSCs that had been cultured and trans-
duced as specified in the retroviral transduction section. After reconstitution,
animals were monitored until they displayed severe morbidity and/or loss of
10% of their starting body weight. For DC depletion experiments, HSCs
derived from CD11c-DTR mice (Jung et al., 2002) were used to generate
chimeras as described above followed by intravenous injection with 200 ng
of diphtheria toxin (Sigma) or saline as indicated in the schematic in Figure 4D.
At the time of sacrifice, bone marrow and spleens were harvested, processed
into single-cell suspensions for counting, and analyzed as previously
described (Barbalat et al., 2009). Experimental groups typically consisted of
three to five mice. Mice were analyzed individually.
Blood Collection and Analysis
Blood was collected by retroorbital bleeding or cardiac puncture. After collec-
tion, blood was divided into aliquots for preparation of sera and for hematolog-
ical analysis. Serum was prepared with serum separator tubes (BD Biosci-
ences) according to manufacturer’s instructions. Erythrocyte, leukocyte, and
hematocrit counts were assayed by the UCSF Comprehensive Cancer Center
Mouse Pathology Core facility, using a HEMAVET Multispecies Hematology
Analyzer. Cytokines in sera samples were analyzed with SearchLight custom
multiplex protein array (Pierce Biotechnology, Inc.). Serum DNA concentra-
tions were measured with Quant-iT dsDNA Assay kit (Invitrogen).
Immunoprecipitation and Immunblot Analyses
Cells were lysed as previously described (Ewald et al., 2008). In brief, cells
were lysed in TNT buffer (20 mM Tris [pH 8.0], 200 mM NaCl, 1% Triton
X-100) or Digitonin lysis buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 5 mM
EDTA [pH 8.0], 1% Digitonin) supplemented with complete protease inhibitor
cocktail (Roche). Lysates were cleared of insoluble material by centrifugation.
For immunoprecipitations, lysates were incubated with anti-HAmatrix (Roche)
or anti-FLAG matrix (Sigma) and precipitated proteins were boiled in SDS
buffer, separated by SDS-PAGE, and probed by anti-HA, anti-FLAG, or
anti-MyD88 immunoblot.
Luciferase Assays
Cells were stimulated with ligands and lysed with Passive Lysis buffer (Prom-
ega) after 16 hr. Luciferase activity was measured on a LMaxII-384 luminom-
eter (Molecular Devices). For plate-bound CpG assays, strepavidin-coatedIplates (Pierce) were blocked overnight with 0.1%BSA in PBS followed by incu-
bation with biotin-CpG ODN (2 hr at room temperature). After extensive
washing, plates were seeded with HEK293 cells stably expressing a NF-kB
luciferase reporter and the TLR of interest. In parallel, cells were seeded
onto TC plates for stimulation with soluble CpG ODN. Cells were lysed after
6 hr and luciferase activity was measured as described above. All assays
were performed in triplicate.
Pulse-Chase Analysis
Cells were starved for 1 hr in cysteine and methionine-free media, then pulsed
with 0.25 mCi 35S-cysteine and methionine (Perkin-Elmer). After a 45 min
pulse, cells were washed and cultured in 5 ml chase media with 10,000-fold
molar excess of L-cysteine, L-methionine or harvested as the zero time point.
Time points were harvested as follows: cells were washed twice in 2 ml PBS
and lysed in 1 ml RIPA plus protease inhibitor cocktail. Labeled HA-tagged
proteins were immunoprecipitated with anti-HA-matrix and visualized with
SDS-PAGE.
Flow Cytometry
For surface marker analysis, cells were preincubated with anti-CD16-CD32
(2.4G2; Monoclonal Antibody Core, University of California, San Francisco)
followed by staining with the indicated antibodies. To measure TNF produc-
tion, brefeldinA was added 30 min after stimulation, cells were collected after
an additional 4 hr, and cells were stained for intracellular cytokines with a
Fixation & Permeabilization kit according to manufacturer’s instructions
(eBioscience). For FLAG-TLR surface expression, HEK293T cells stably
expressing FLAG-TLR9, FLAG-TLR9TM-MUT, or FLAG-TLR2 were stained
with anti-FLAG (M5) antibody followed by Alexa 647 goat anti-mouse IgG
secondary antibody. All data were collected on LSR II (Becton Dickinson)
or FC-500 (Beckman Coulter) flow cytometers and were analyzed with FloJo
software (TreeStar).
Statistical Analysis
Student’s paired t test was used for statistical comparison. p values represent
comparison of TLR9TM-MUT with wild-type TLR9. Prism software was used for
all analyses (Graphpad Software).
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.immuni.2011.10.009.
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